Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2022; 10(7): 2115-2126
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Develop a nomogram to predict overall survival of patients with borderline ovarian tumors
Xiao-Qin Gong, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Yan Zhang, Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Gong XQ and Zhang Y designed and performed the research, collected and analyzed the data; Gong XQ wrote the manuscript; Zhang Y revised the draft; all authors have read and approved the final manuscript.
Supported by National Key Technology R&D Program of China , No. 2019YFC1005200, No. 2019YFC1005202, and No. 2018YFC1002103.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Tongji Hospital of Tongji Medical College at Huazhong University of Science and Technology Institutional Review Board (Approval No. TJ-IRB20190321).
Conflict-of-interest statement: The authors declare there are no conflicts of interest.
Informed consent statement: The data were anonymous and analyzed retrospectively. In accordance with the rules of the ethics committee, this study applied for exemption from informed consent.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Zhang, MD, Doctor, Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, Hubei Province, China. 283427856@qq.com
Received: November 29, 2021
Peer-review started: November 29, 2021
First decision: January 12, 2022
Revised: January 17, 2022
Accepted: February 23, 2022
Article in press: February 23, 2022
Published online: March 6, 2022
Processing time: 92 Days and 21.5 Hours
Peer-review started: November 29, 2021
First decision: January 12, 2022
Revised: January 17, 2022
Accepted: February 23, 2022
Article in press: February 23, 2022
Published online: March 6, 2022
Processing time: 92 Days and 21.5 Hours
Core Tip
Core Tip: The recurrence and overall survival of borderline ovarian tumors (BOTs) after operation have been one of the main concerns of patients and clinicians. In this research, we firstly performed a 1:1 propensity score matching analysis by applying age as a matching variable, then we found that patients with BOTs had a better overall survival as compared to patients with epithelial ovarian cancer (EOC), more importantly, the 5-year restricted mean survival time of BOTs was longer than EOC. What’s more, we conducted a nomogram that could accurately predict 1, 3, 5-year overall survival in patients with BOTs.